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Background: Outcomes for children diagnosed with cancer have improved dramatically over the past 20 years.
However, although 40% of pediatric cancer patients require at least one intensive care admission throughout
their disease course, PICU outcomes and resource utilization by this population have not been rigorously studied
in this speciﬁc group.
Methods: Using a systematic strategy, we searched Medline, Embase, and CINAHL databases for articles de-
scribing PICU mortality of pediatric cancer patients admitted to PICU. Two investigators independently applied
eligibility criteria, assessed data quality, and extracted data. We pooled PICU mortality estimates using random-
eﬀects models and examined mortality trends over time using meta-regression models.
Results: Out of 1218 identiﬁed manuscripts, 31 studies were included covering 16,853 PICU admissions with the
majority being retrospective in nature. Overall pooled weighted mortality was 27.8% (95% conﬁdence interval
(CI), 23.7–31.9%). Mortality decreased slightly over time when post-operative patients were excluded. The use
of mechanical ventilation (odds ratio (OR): 18.49 [95% CI 13.79–24.78], p < 0.001), inotropic support (OR:
14.05 [95% CI 9.16–21.57], p < 0.001), or continuous renal replacement therapy (OR: 3.24 [95% CI
1.31–8.04], p=0.01) was signiﬁcantly associated with PICU mortality.
Conclusions: PICU mortality rates of pediatric cancer patients are far higher when compared to current mortality
rates of the general PICU population. PICU mortality has remained relatively unchanged over the past decades, a
slight decrease was only seen when post-operative patients were excluded. This compared infavorably with the
improved mortality seen in adults with cancer admitted to ICU, where research-led improvements have led to the
paradigm of unlimited, aggressive ICU management without any limitations on resuscitations status, for a time-
limited trial.
1. Introduction
Over the last decades, enhanced cancer therapy included the in-
troduction of intensiﬁed multimodality treatment protocols, better
stratiﬁcation and advanced supportive care. Consequently, survival of
children diagnosed with cancer has increased from an overall estimated
20% in the late 1980s to 70–80% survival today. (Bleyer, 1997;
Petridou et al., 2013; Pritchard-Jones et al., 2006) However, intensiﬁed
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treatment regimens have also increased the incidence of treatment-re-
lated side eﬀects and toxicities, many of which require intensive care
treatment (Kress et al., 1999; Staudinger et al., 2000; Dalton et al.,
2003; Tamburro et al., 2008) Recent studies showed that about 40% of
all pediatric cancer patients require admission to the pediatric intensive
care unit (PICU) at some point during their disease course, with acute
respiratory failure and sepsis being the main admission reasons (Dalton
et al., 2003; Tamburro et al., 2008; Hallahan et al., 2000; Rosenman
et al., 2005)
Children with cancer requiring intensive care support are a highly
complex and challenging group, with signiﬁcantly worse outcomes
compared to the overall PICU population. (Dalton et al., 2003;
Tamburro et al., 2008), However, in adult cancer patients it has been
shown that early institution of intensive care support rather than not
intervening until late in the spiral of multi-organ failure, has sig-
niﬁcantly improved survival (Azoulay et al., 2013; Lengliné et al., 2012;
Mokart et al., 2013)
PICU outcome and resource utilization in the pediatric cancer po-
pulation have not been rigorously studied. Lack of this information is an
important problem, as more knowledge could allow for better under-
standing of underlying mechanisms of organ dysfunction, identifying
risk factors for clinical deterioration, more timely administration of life-
saving therapies, and more cost-eﬀective delivery of care and utiliza-
tion of PICUs. So far, most of the existing data come from small, single-
center retrospective studies.
In view of the limitations of the existing literature, we conducted a
systematic review and meta-analysis using a comprehensive search
strategy and meta-regression analysis to document PICU mortality for
pediatric cancer patients, and to evaluate whether this PICU mortality
has changed over time. Our aim is that in delineating the current si-
tuation we can then design prospective interventional trials.
2. Methods
This systematic review and meta-analysis followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis guidelines
(the PRISMA checklist is listed in eTable 1). (Moher et al., 2009, 2015),
The protocol was registered on PROSPERO (ID: CRD42018091406).
2.1. Search strategy
A systematic comprehensive electronic search of MEDLINE,
EMBASE, and CINAHL was undertaken, using a detailed search. All
resources were searched from inception to March 2017. Databases were
electronically searched for relevant publications using combinations of
the following medical subject headings (MeSH) and keywords
[Neoplasms] AND [Pediatric] AND [Intensive Care Unit, Pediatric]
AND [Mortality]. Reviewing references of included studies and reviews
expanded the search. Complete details of the study methods are pro-
vided in eTable2. The search was restricted to English-language articles.
2.2. Inclusion and exclusion criteria
To be included in the review, the study had to report PICU mortality
in patients with a known malignancy who had been admitted to a PICU.
Conference proceedings, reviews, editorials, letters or case reports,
publications in abstract form only, studies including only one subtype
of cancer (e.g., AML), and duplicate reports were excluded. Also, stu-
dies including exclusively hematopoietic stem cell transplant patients
were assessed whether data on cancer patients could be extracted as a
large part of the reported patients have a non-malignant underlying
disease. If not, these studies were excluded. In addition, studies from
developing countries were excluded due to the reduced accessibility of
resources and diﬀerences in standard of care compared to non-devel-
oping countries.
2.3. Selection of studies and data extraction
Titles and abstracts of all reports identiﬁed in the literature search
were screened by two authors for further review with discrepancies
resolved by consensus. Full text review of eligibility was conducted by
two authors independently and relevant data was extracted from in-
cluded studies to a standard piloted form.
For each study included in the ﬁnal analysis, the following data
were extracted: study design, years of study conduct, geographic loca-
tion, patients’ age and gender, underlying malignancy, and reason of
PICU admission. The primary outcome was PICU mortality. Key sec-
ondary outcomes included length of PICU stay, PICU resources use such
as invasive mechanical ventilation, inotropic/vasopressor support, and
continuous renal replacement therapy (CRRT). We used the median
year of the study enrollment period as the year of study conduct. Two
studies provided mortality data for diﬀerent cohorts (Butt et al., 1988;
Heying et al., 2001); we included each cohort as an individual study.
Data of the study populations were summarized using proportions
and weighted means. The mean and standard deviations in individual
studies were estimated from those that were reported as median and
interquartile range by using the method described by Wan et al. (Wan
et al. (2014))
2.4. Assessment of quality
Methodological quality (risk of bias assessment) of each study was
assessed using a 13-item list based on the STROBE guidelines.
(Viswanathan et al., 2019; Sanderson et al., 2007; Vandenbroucke
et al., 2007) Each item was scored as high quality (1 point) or low
quality (0 points). The overall quality score is the percentage of items
scored as high quality and is categorized in high (> 80%) and low
(<80%) quality studies.
2.5. Data analysis
We performed a meta-analysis using DerSimonian-Laird random
eﬀects models to obtain overall pooled weighted PICU mortality with
95% conﬁdence intervals (CIs). A subgroup analysis was performed on
a subset of studies in which post-operative patients were excluded and
an analysis of this latter group including only studies in which no
speciﬁc PICU admission reasons (e.g. patients with ARDS) were used,
and on a subset of patients with sepsis at admission.
Heterogeneity of pooled data was assessed by using I2 statistic. The
I2 statistic describes the percentage of total variation across studies due
to true heterogeneity rather than chance. Values greater than 50%
suggest substantial heterogeneity. (Higgins et al., 2003; Higgins and
Geen, 2011), Publication bias was assessed by constructing a funnel
plot and by using the Begg & Mazumdar’s rank correlation test.
Separate random-eﬀects logistic meta-regression analyses were used
to explore the association between mortality, intervention-speciﬁc
mortality (mechanical ventilation, inotropic support or CRRT), and year
of study conduct. In addition, linear regression analysis was performed
to explore the association of methodological quality of each study and
year of publication. Finally, in a post hoc analysis, separate
DerSimonain-Laird random eﬀects models were used to explore the
association between use of PICU resources and mortality. Other pre-
disposing factors, such as underlying malignancy and PICU admission
diagnosis, could not be explored due to the mixture of used deﬁnitions.
Data are presented as odds ratios with p values.
A p-value of less than 0.05 was considered signiﬁcant. All statistical
analyses were performed using OpenMeta[analyst] (http://www.cebm.
brown.edu/open-meta).
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3. Results
3.1. Study selection
The search was conducted up to March 2017. The search identiﬁed a
total of 1218 publications (Fig. 1). Overall inter-reviewer agreement for
study selection was substantial (κ=0.80). After duplicate removal and
abstract screening, 66 articles were considered for full-text analysis.
Among them, 35 were excluded because they did not turn out to meet
inclusion criteria. The remaining 31 studies (total 14,312 patients with
16,853 PICU admissions) were included in our review. (Dalton et al.,
2003; Tamburro et al., 2008; Hallahan et al., 2000; Butt et al., 1988;
Heying et al., 2001; Meert et al., 1991; Sivan et al., 1991; van Veen
et al., 1996; Heney et al., 1992; Parsons et al., 2001; Ben-Abraham
et al., 2001; Ben Abraham et al., 2002; Keengwe et al., 1999; Fiser et al.,
2005; Kutko et al., 2003; Khattab et al., 2005; da Silva et al., 2008;
Pound et al., 2008; Tamburro et al., 2004; Pancera et al., 2008; Meyer
et al., 2005; Haase et al., 2011; Schiller et al., 2009; Faraci et al., 2014;
Owens et al., 2011; Dursun et al., 2009; Fausser et al., 2017; Ha et al.,
2010; Garcia-Salido et al., 2015; Zinter et al., 2014; Agulnik et al.,
2016)
3.2. Description of included studies
The characteristics of the included studies are summarized in
Table 1. The majority of the studies were retrospective, single center
cohort studies. Ten studies were conducted in North America, two in
South
America, eleven studies in Europe, one in Asia, one in Australia,
four in the Middle East, and two were combined studies (Canada/
Australia and USA/Israel). Sample sizes ranged from 13 (Heying et al.,
2001) to 10,365 (Zinter et al., 2014). In- and exclusion criteria varied
signiﬁcantly between the studies (Table 1 and eTable 3 for a detailed
description of in- and exclusion criteria). Most studies included pedia-
tric patients with a primary diagnosis of cancer who were admitted to
the PICU. Ten studies included only a subgroup of pediatric cancer
patients; four included only septic patients (Fiser et al., 2005; Kutko
et al., 2003; da Silva et al., 2008; Pound et al., 2008), four studies in-
cluded patients requiring mechanical ventilation (invasive or non-in-
vasive) (Tamburro et al., 2008; Pancera et al., 2008; Schiller et al.,
2009; Ha et al., 2010), one study included ARDS patients (Ben-
Abraham et al., 2001), and ﬁnally one study included patients with
respiratory insuﬃciency (Garcia-Salido et al., 2015). Ten studies ex-
cluded post-operative patients at the start of the study.
Twenty-nine studies reported the underlying oncological diagnosis.
The main diagnoses included leukemia/lymphoma (46%), solid tumors
(22%), brain and spinal cord tumors (30%), and other/non-malignant
diseases (2%).
3.3. Methodological quality and risk of bias
Methodological quality of the included studies ranged from 58% to
100%. Eighteen out of the 31 included studies (58%) were considered
to be of high quality. (Dalton et al., 2003; Tamburro et al., 2008;
Hallahan et al., 2000; Ben-Abraham et al., 2001; Kutko et al., 2003; da
Silva et al., 2008; Pound et al., 2008; Tamburro et al., 2004; Meyer
et al., 2005; Haase et al., 2011; Schiller et al., 2009; Faraci et al., 2014;
Dursun et al., 2009; Fausser et al., 2017; Ha et al., 2010; Garcia-Salido
et al., 2015; Zinter et al., 2014; Agulnik et al., 2016) Detailed quality
assessment of the included studies is provided in eTable 4. The quality
of the studies improved over time (eFig. 1). We did not ﬁnd signiﬁcant
publication bias (eFig. 2).
Fig. 1. Flow chart of study selection.
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3.4. PICU mortality
The overall pooled weighted PICU mortality was 27.8% (95% CI,
23.7–31.9) (Fig. 2). When excluding post-operative patients, pooled
weighted PICU mortality increased to 33.5% (95% CI, 27.0–40.0)
(Fig. 3).
As this latter cohort still contained studies with a variety of inclu-
sion criteria, we performed an additional analysis on those studies that
have included all PICU admission diagnoses, thereby representing a
general PICU cohort of pediatric cancer patients. Pooled PICU mortality
of this group was 35.4% (95% CI, 26.7–44.0) (Fig. 4). Among patients
with sepsis, the estimated pooled PICU mortality was 46.2% (95% CI,
34.7–57.8) (Fig. 5). There was signiﬁcant heterogeneity for PICU
mortality across all studies (I2=96%, p < 0.001), across studies ex-
cluding post-operative patients (I2=97%, p < 0.001), and across
studies including only septic patients (I2=93%, p < 0.001).
Fig. 6 depicts the pooled weighted PICU mortality by year of study
conduct. There was no association between the median year of study
conduct and the reported PICU mortality (Fig. 56A). However, a slight,
but signiﬁcant, decrease in PICU mortality over time was found when
post-operative patients were excluded (Fig. 56B). In the latter group in
which only studies that have included all PICU admission diagnoses
were selected (Fig. 56C) and in the subset of septic cancer patients, no
signiﬁcant decrease of PICU mortality over time was found (Fig. 56D).
3.5. Use of PICU resources
A majority of the studies (25 out of 31, 80.6%) reported on the use
of PICU resources such as mechanical ventilation, inotropes, and/or
CRRT. (Dalton et al., 2003; Tamburro et al., 2008; Hallahan et al.,
2000; Butt et al., 1988; Heying et al., 2001; Meert et al., 1991; van Veen
et al., 1996; Heney et al., 1992; Ben-Abraham et al., 2001; Ben
Abraham et al., 2002; Keengwe et al., 1999; Fiser et al., 2005; Khattab
et al., 2005; da Silva et al., 2008; Tamburro et al., 2004; Pancera et al.,
2008; Meyer et al., 2005; Haase et al., 2011; Faraci et al., 2014; Owens
et al., 2011; Dursun et al., 2009; Fausser et al., 2017; Ha et al., 2010;
Garcia-Salido et al., 2015; Zinter et al., 2014) Thirty percent of the
reported patients (4315/14142) received mechanical ventilation. The
use of inotropes was described 21 studies. Forty percent (1240/3117) of
the reported patients received inotropes. Only ten studies reported the
use of CRRT during the PICU stay with 4,6% (382 of 8339 patients)
requiring CRRT. Sixteen studies described PICU mortality by PICU
treatment. Use of all three PICU resources was signiﬁcantly associated
with increased PICU mortality (mechanical ventilation odds ratio (OR)
18.49 [95% CI 13.79–24.78], p < 0.001; inotropic support OR 14.05
[95% CI 9.16–21.57], p < 0.001; CRRT OR 3.24 [95% CI 1.31–8.04],
p= 0.01) (Table 2 ). Over time, intervention-speciﬁc PICU mortality
improved, albeit only signiﬁcant in patients who required inotropic
support (eFig. 3).
4. Discussion
This systematic review of 31 observational studies over the past 30
years showed the mortality of pediatric cancer patients admitted to
PICU is high (28%), ﬁve-fold higher than the current mortality rate of
the general PICU population. (Heneghan and Pollack, 2017) When post-
operative patients were excluded, PICU mortality increased to 33% and
was even higher in septic patients (46%). Overall, mortality rates have
remained static over time, although when post-operative patients were
excluded, there is a slight signiﬁcant decrease of PICU mortality over
the past decades. For septic cancer patients, no association between the
median year of study conduct and reported PICU mortality was found.
The need for PICU resources (mechanical ventilation, inotropic support
and CRRT) was signiﬁcantly associated with PICU mortality.
Our ﬁndings are in line with previously reported high mortality
rates of adult cancer patients requiring ICU admission. However, inTa
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contrast to our results, the ICU survival of adult patients has improved
substantially over the corresponding time-frame. (Shimabukuro-
Vornhagen et al., 2016) There are several diﬀerences between the ap-
proaches of adult and pediatric intensivists to critically ill cancer pa-
tients. One main explanation is that signiﬁcant research into the man-
agement of critically ill adult cancer patients has occurred compared to
children. This has resulted in changes to the point of view regarding
admission of critically ill adult cancer patients to ICU over the past 15
years. (Azoulay et al., 2017) Time-limited trials of therapy, the so-called
ICU-trials, have been one of these major changes (Shrime et al., 2016).
The ICU-trial consists of unlimited, aggressive ICU management with
full resuscitation status for a speciﬁc limited period. In one large
French/Belgian study, critically ill patients with cancer, those with
hematologic malignancies or less severe illness beneﬁted most from
longer duration of trials (at least 2 weeks) of intensive care; whereas for
patients with poor-prognostic solid tumors, shorter trial durations of 1
to 4 days were enough to provide the comparable survival to unlimited
aggressive care (Azoulay et al., 2013). In addition, it was demonstrated
that ICU-admission shortly after the start of the critical care illness was
associated with better survival rates. (Azoulay et al., 2013) Whether
this approach would also improve PICU survival in pediatric cancer
patients, needs to be determined.
Mortality trends over time oﬀer important insights into the state of
medical care for a particular disease or patient cohort. Mark Peters and
Rachel Agbeko showed that the predicted risk of mortality for children
with leukemia or lymphoma outside of ﬁrst remission admitted to PICU
due to sepsis-induced multiple organ dysfunction syndrome or ARDS
has improved over the past decades. (Peters and Agbeko, 2014) How-
ever, our results suggest only slightly decreasing mortality rates over
time when post-operative patients were excluded. Improved survival
may be related to signiﬁcant advances in ICU care, such as the in-
troduction of early-goal directed therapy for sepsis and lung-protective
ventilation. (Rhodes et al., 2017; Kneyber et al., 2017), Also, oncology
treatments as well as supportive care such as immunomodulation have
improved signiﬁcantly in the past decades. Although guidelines exist to
promote these practices, variable adherence may contribute to the ob-
served lack of improvement in actual PICU outcomes of these patients.
In addition, development of aggressive treatment regimens against
cancer may have increased requirements of PICU support with the use
of life-sustaining therapies for infectious or toxic chemotherapy-related
events. This may imply that a higher-risk cohort of patients are being
admitted to PICU over time, and because overall PICU care has im-
proved, the mortality for these patients has not increased. As most
studies did not report on severity of illness scores, such as PIM or PRISM
scores, we were not able to verify this. In addition, it is possible that
improved overall management of pediatric cancer patients means only
those with more advanced disease or severe complications are now
referred to PICU.
Not surprisingly, the need for PICU treatments such as mechanical
ventilation, inotropic support and/or CRRT is associated with increased
mortality. However, intervention-speciﬁc PICU mortality decreased
over time. These results are consistent with ﬁndings in critically ill
adult cancer patients where mortality has decreased over the past years.
(Shimabukuro-Vornhagen et al., 2016; Azoulay et al., 2014), This may
be attributable to improvements in early recognition of critically ill
cancer patients, rapid implementation of aggressive ICU treatments,
intensivists’ skills in understanding the pathophysiology of organ dys-
function in this population and management of urgent complications
Fig. 2. Forest plot of PICU mortality using a random-eﬀects model.Individual mortality for each study and the pooled weighted estimate shown with 95% conﬁdence
intervals (CI). Vertical dotted line represents the pooled weighted estimate. For studies providing PICU mortality for diﬀerent time periods or cohorts, an individual
point estimate is provided for each period.
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Fig. 3. Forest plot of PICU mortality for pediatric cancer patients excluding post-operative patients using a rondom-eﬀects model.Individual mortality for each study
and the pooled weighted estimate shown with 95% conﬁdence intervals (CI). Vertical dotted line represents the pooled weighted estimate. For studies providing PICU
mortality for diﬀerent time periods or cohorts, an individual point estimate is provided for each period.
Fig. 4. Forest plot of PICU mortality for pediatric cancer patients, excluding post-operative patients using a rondom-eﬀects model. Only studies that have included all
PICU admission diagnoses were analyzed.Individual mortality for each study and the pooled weighted estimate shown with 95% conﬁdence intervals (CI). Vertical
dotted line represents the pooled weighted estimate. For studies providing PICU mortality for diﬀerent time periods or cohorts, an individual point estimate is
provided for each period.
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related to the malignancy. These developments must challenge pedia-
tric intensivists and oncologists to achieve the same goals. To this aim,
we need to collaborate intensively to generate prospective data on
outcome, using identical criteria of underlying malignancies, admission
diagnoses in order to determine risk factors on mortality.
Our study has important limitations. Our ﬁndings should be inter-
preted with caution due to the retrospective nature of the majority of
the studies, which render them susceptible to potential ﬂaws and bias.
There was a considerable heterogeneity among published cohorts. This
likely reﬂects diﬀerences in terms of case- mix, center characteristics,
treatment strategies, and PICU admission criteria. Especially, in- and
exclusion criteria of the included studies diﬀered signiﬁcantly.
Moreover, the majority of the included studies didn’t report on the
inclusion of HSCT patients. Inclusion of these patients may have in-
ﬂuenced PICU mortality rates over time. Almost all studies performed
after 2000 reported inclusion of HSCT patients. `Previous studies have
shown that these patients have a high PICU mortality (Pillon et al.,
2017; An et al., 2016; Chima et al., 2012; van Gestel et al., 2008; Lamas
et al., 2003). Increased numbers of included HSCT patients over time
may form an explanation for the unchanged PICU mortality over the
past decades. An individual patient data meta-analysis will be needed to
adjust adequately for these confounders. In particular, we could not
investigate the association between underlying malignancy or PICU
admission diagnosis and mortality, because in the majority of the stu-
dies these data was not speciﬁed. For this reason, studies with only one
subtype of cancer were excluded due to the fact that this data would not
represent a general PICU mortality of pediatric cancer patients. Simi-
larly, we could only investigate the association between use of PICU
resources and mortality in a univariate analysis, as many studies did not
report on the use of a combination of resources (e.g. mechanical ven-
tilation with inotropes). Studies including exclusively hematopoietic
stem cell transplant patients were also excluded. The majority of these
studies included also children with a non-malignant disease without
providing data of PICU mortality of the cancer patients separately.
Moreover, this subpopulation of patients is known to have a high
mortality rate, again not representing a general PICU mortality of pe-
diatric cancer patients (Pillon et al., 2017; An et al., 2016; Chima et al.,
2012; van Gestel et al., 2008; Lamas et al., 2003). We used the median
year of conduct for each study as the independent variable in analyses
of the eﬀect of year on mortality. This was necessary because all studies
were conducted over several decades. Finally, most studies reﬂect the
experience of a single center thereby these results may be of limited
generalizability to international healthcare systems with diﬀerent
practice patterns.
Our analysis may have important implications for pediatric in-
tensivists and oncologists. We show that the improved overall survival
rates of pediatric cancer patients are not reﬂected in the cohort referred
to PICU. Although it cannot be excluded that over time this speciﬁc
patient population forms a higher-risk cohort, an overall PICU mortality
of almost 35% is too high and that is evidence enough to focus on
tailoring research to improve outcomes in this patient population.
Tantalizingly, the improvement in adult cancer patients in ICU suggests
improvement is possible, but caution is warranted as we have little
basic data on changes in the population referred. More research is
needed to improve our ability to appropriately treat these patients.
Recognizing the need for international collaboration on this issue, the
PICU Oncology Kids in Europe Research group (POKER) was estab-
lished to address these items ultimately to improve outcomes of chil-
dren with cancer who are admitted to the PICU. As a ﬁrst step, POKER
aims to obtain consensus in determining the top research priorities and
core outcome measures in the ﬁeld of pediatric cancer patients at the
PICU for the next 10 years.
In conclusion, our systematic review has shown that PICU mortality
in pediatric cancer patients is sadly high and, unlike in adults with
cancer, has remained relatively unchanged over the past decades. Our
results highlight the need for urgent multicenter prospective interven-
tional studies in this cohort. These studies may reveal risk factors for
clinical deterioration and eﬀective therapeutic interventions. In addi-
tion, data from these studies may help guide both intensivists and on-
cologists in risk stratiﬁcation for patients, in the decision-making pro-
cess of allocation of PICU resources, and may identify patients that may
beneﬁt from closer monitoring and early interventions. Finally, these
studies may advance our understanding of critical illness in the context
of pediatric oncology to further reﬁne and reﬂect on our daily clinical
practice.
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Fig. 5. Forest plot of PICU mortality for pediatric cancer patients with sepsis using a random-eﬀects model.Individual mortality for each study and the pooled
weighted estimate shown with 95% conﬁdence intervals (CI). Vertical dotted line represents the pooled weighted estimate. For studies providing PICU mortality for
diﬀerent time periods or cohorts, an individual point estimate is provided for each period.
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